In the past year, the results of three studies in the field of prostate cancer imaging — the prostate MR imaging study (PROMIS), an analysis of the cost-effectiveness of various diagnostic strategies based on PROMIS data, and a retrospective analysis of a prostate-specific membrane antigen (PSMA)-directed PET radiopharmaceutical — have been published that could have lasting effects on clinical practice.
Subscribe to Journal
Get full journal access for 1 year
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Ahmed, H. U. et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389, 815–822 (2017).
Faria, R. et al. Optimising the diagnosis of prostate cancer in the era of multiparametric magnetic resonance imaging: a cost-effectiveness analysis based on the prostate MR imaging study (PROMIS). Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2017.08.018 (2017).
Afshar-Oromieh, A. et al. Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur. J. Nucl. Med. Mol. Imaging 44, 1258–1268 (2017).
Moldovan, P. C. et al. What is the negative predictive value of multiparametric magnetic resonance imaging in excluding prostate cancer at biopsy? A systematic review and meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. Eur. Urol. 72, 250–266 (2017).
Delongchamps, N. B. et al. Prebiopsy magnetic resonance imaging and prostate cancer detection: comparison of random and targeted biopsies. J. Urol. 189, 493–499 (2013).
Puech, P. et al. Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy — prospective multicenter study. Radiology 268, 461–469 (2013).
Gillessen, S. et al. Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC 2017. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2017.06.002 (2017).
Vargas, H. A. et al. Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1 ng/ml following prostatectomy: how much information can conventional imaging provide? Urol. Oncol. 34, 482.e5–482.e10 (2016).
Nanni, C. et al. 18F-FACBC (anti1-amino-3-18F-fluorocyclobutane-1-carboxylic acid) versus 11C-choline PET/CT in prostate cancer relapse: results of a prospective trial. Eur. J. Nucl. Med. Mol. Imaging 43, 1601–1610 (2016).
von Eyben, F. E. et al. 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography for prostate cancer: a systematic review and meta-analysis. Eur. Urol. Focus http://dx.doi.org/10.1016/j.euf.2016.11.002 (2016).
The authors thank Ada Muellner, MS, of Memorial Sloan Kettering Cancer Center, who helped edit the manuscript before submission.
A.G.W. has received support from the Peter Michael Foundation. H.H. serves on the Board of Directors of Ion Beam Application (IBA), a role for which she receives annual compensation.
About this article
Cite this article
Wibmer, A., Vargas, H. & Hricak, H. Advances in imaging. Nat Rev Urol 15, 81–82 (2018). https://doi.org/10.1038/nrurol.2017.210